Viral Meningitis Is a Central Nervous System (CNS) Infection Characterized
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Rotavirus Vaccine for the Prevention of Rotavirus Gastroenteritis Among Children
March 19, 1999 / Vol. 48 / No. RR-2 Recommendations and Reports Rotavirus Vaccine for the Prevention of Rotavirus Gastroenteritis Among Children Recommendations of the Advisory Committee on Immunization Practices (ACIP) Continuing Education Examination Education Continuing Inside: U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Disease Control and Prevention (CDC) Atlanta, Georgia 30333 The MMWR series of publications is published by the Epidemiology Program Office, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333. SUGGESTED CITATION Centers for Disease Control and Prevention. Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999;48(No. RR-2):[inclu- sive page numbers]. Centers for Disease Control and Prevention....................Jeffrey P. Koplan, M.D., M.P.H. Director The material in this report was prepared for publication by National Center for Infectious Diseases.................................. James M. Hughes, M.D. Director Division of Viral and Rickettsial Diseases ................. Brian W. J. Mahy, Ph.D., Sc.D. Director National Immunization Program ...........................................Walter A. Orenstein, M.D. Director Epidemiology and Surveillance Division ...........................John R. Livengood, M.D. Director The production of this report as an MMWR serial publication was coordinated in Epidemiology Program Office.................................... Stephen B. Thacker, M.D., M.Sc. Director Office of Scientific and Health Communications ......................John W. Ward, M.D. Director Editor, MMWR Series Recommendations and Reports................................... Suzanne M. Hewitt, M.P.A. Managing Editor Valerie R. Johnson Project Editor Morie M. Higgins Visual Information Specialist Vol. 48 / No. RR-2 MMWR i Contents Clinical and Epidemiologic Features of Rotavirus Disease............................................. -
Viral Encephalitis and Meningitis
Peachtree Street NW, 15th Floor Atlanta, Georgia 30303-3142 Georgia Department of Public Health www.health.state.ga.us Viral Encephalitis and Viral (Aseptic) Meningitis Frequently Asked Questions What are viral encephalitis and viral meningitis? Viral encephalitis is inflammation (or swelling) of the brain caused by a viral infection. Symptoms of viral encephalitis include headache, fever, stiff neck, seizures, changes in consciousness such as confusion or coma, and sometimes death. Viral (or aseptic) meningitis is also caused by a viral infection resulting in inflammation (or swelling) of the meninges, the protective covering of the brain and spinal cord. The symptoms of viral meningitis are similar to those of viral encephalitis, although loss of or changes in consciousness are not common symptoms of viral meningitis. Viral and bacterial meningitis are not caused by the same organisms, and viral meningitis is usually not as serious as bacterial meningitis. What causes viral encephalitis and viral (aseptic) meningitis? Organisms called viruses cause viral encephalitis and viral meningitis. Many different types of viruses cause these illnesses. Some of these viruses can be passed from person to person, such as when people (especially young children) do not practice good hygiene by washing their hands thoroughly. Other viruses can be passed to people through the bites of infected mosquitoes or ticks. When do most cases of viral encephalitis and viral meningitis occur? Viral encephalitis and viral meningitis occur year‐round. Encephalitis from mosquito bites usually occurs in the late summer and fall, when mosquitoes are most active. Tick‐borne viral encephalitis usually occurs in the spring and early summer, although cases of tick‐borne encephalitis have never been documented in Georgia. -
Attenuation of Human Respiratory Syncytial Virus by Genome-Scale Codon-Pair Deoptimization
Attenuation of human respiratory syncytial virus by genome-scale codon-pair deoptimization Cyril Le Nouëna,1, Linda G. Brocka, Cindy Luongoa, Thomas McCartya, Lijuan Yanga, Masfique Mehedia, Eckard Wimmerb,1, Steffen Muellerb,2, Peter L. Collinsa, Ursula J. Buchholza,3, and Joshua M. DiNapolia,3,4 aRNA Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892; and bDepartment of Molecular Genetics and Microbiology, Stony Brook University, Stony Brook, NY 11794 Contributed by Eckard Wimmer, June 18, 2014 (sent for review February 14, 2014) Human respiratory syncytial virus (RSV) is the most important viral acid coding is unaffected, CPD strains provide the same reper- agent of serious pediatric respiratory-tract disease worldwide. A toire of epitopes for inducing cellular and humoral immunity as vaccine or generally effective antiviral drug is not yet available. the WT pathogen. Recently, the CPD approach has been used We designed new live attenuated RSV vaccine candidates by successfully to attenuate poliovirus, influenza A virus, Strepto- codon-pair deoptimization (CPD). Specifically, viral ORFs were recoded coccus pneumonia, and HIV type 1 (5, 10–13). by rearranging existing synonymous codons to increase the content In the present work, four CPD RSV genomes were designed, of underrepresented codon pairs. Amino acid coding was com- synthesized, and recovered by reverse genetics. The CPD pletely unchanged. Four CPD RSV genomes were designed in recombinant (r) RSVs were attenuated and temperature- which the indicated ORFs were recoded: Min A (NS1, NS2, N, P, sensitive in vitro. Furthermore, we demonstrated that the CPD M, and SH), Min B (G and F), Min L (L), and Min FLC (all ORFs except rRSVs were attenuated and immunogenic in mice and African M2-1 and M2-2). -
Hepatitis B Vaccine – Frequently Asked Questions (Information from the CDC)
AAMC Standardized Immunization Form 2020 Hepatitis B Vaccine – Frequently Asked Questions (Information from the CDC) 1. What are the hepatitis B vaccines licensed for use in the United States? Three single-antigen vaccines and two combination vaccines are currently licensed in the United States. Single-antigen hepatitis B vaccines: • ENGERIX-B® • RECOMBIVAX HB® • HEPLISAV-B™ Combination vaccines: • PEDIARIX®: Combined hepatitis B, diphtheria, tetanus, acellular pertussis (DTaP), and inactivated poliovirus (IPV) vaccine. Cannot be administered before age 6 weeks or after age 7 years. • TWINRIX®: Combined Hepatitis A and hepatitis B vaccine. Recommended for people aged ≥18 years who are at increased risk for both HAV and HBV infections. 2. What are the recommended schedules for hepatitis B vaccination? The vaccination schedule most often used for children and adults is three doses given at 0, 1, and 6 months. Alternate schedules have been approved for certain vaccines and/or populations. A new formulation, Heplisav-B (HepB-CpG), is approved to be given as two doses one month apart. 3. If there is an interruption between doses of hepatitis B vaccine, does the vaccine series need to be restarted? No. The series does not need to be restarted but the following should be considered: • If the vaccine series was interrupted after the first dose, the second dose should be administered as soon as possible. • The second and third doses should be separated by an interval of at least 8 weeks. • If only the third dose is delayed, it should be administered as soon as possible. 4. Is it harmful to administer an extra dose of hepatitis B vaccine or to repeat the entire vaccine series if documentation of the vaccination history is unavailable or the serology test is negative? No, administering extra doses of single-antigen hepatitis B vaccine is not harmful. -
Wastewater Based Epidemiology Perspective As a Faster Protocol for Detecting Coronavirus RNA in Human Populations: a Review with Specific Reference to SARS-Cov-2 Virus
pathogens Review Wastewater Based Epidemiology Perspective as a Faster Protocol for Detecting Coronavirus RNA in Human Populations: A Review with Specific Reference to SARS-CoV-2 Virus Milad Mousazadeh 1,2,†,‡ , Razieh Ashoori 3, Biswaranjan Paital 4 , I¸sıkKabda¸slı 5,‡ , Zacharias Frontistis 6 , Marjan Hashemi 7 , Miguel A. Sandoval 8,9,‡ , Samendra Sherchan 10, Kabita Das 11 and Mohammad Mahdi Emamjomeh 12,* 1 Student Research Committee, Qazvin University of Medical Sciences, Qazvin, Iran; [email protected] 2 Department of Environmental Health Engineering, School of Health, Qazvin University of Medical Sciences, Qazvin, Iran 3 Department of Environmental Health Engineering, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran; [email protected] 4 Redox Regulation Laboratory, College of Basic Science and Humanities, Odisha University of Agriculture and Technology, Bhubaneswar 751003, India; [email protected] 5 Environmental Engineering Department, Civil Engineering Faculty, Ayaza˘gaCampus, Istanbul˙ Technical University, Istanbul˙ 34469, Turkey; [email protected] 6 Department of Chemical Engineering, University of Western Macedonia, 50132 Kozani, Greece; Citation: Mousazadeh, M.; Ashoori, [email protected] 7 Environmental and Occupational Hazards Control Research Center, Shahid Beheshti University of Medical R.; Paital, B.; Kabda¸slı,I.; Frontistis, Sciences, Tehran, Iran; [email protected] Z.; Hashemi, M.; Sandoval, M.A.; 8 Laboratorio de Electroquímica Medio Ambiental LEQMA, Departamento -
Preventing Polio WHO Myanmar Newsletter Special , 5 August 2019
Preventing polio WHO Myanmar newsletter special , 5 August 2019 What is polio? Poliomyelitis (polio) is a highly infectious disease that is caused when the polio virus invades the nervous system of an infected person. Polio can cause paralysis and even death. Who is most at risk for polio? Poliovirus usually affects children under 5 years of age who are unvaccinated or under-vaccinated. The virus can also affect or be carried by adolescents and adults. photo credit: Ms Lei Lei Mon, WHO Myanmar The child or individual suspected of polio may A child receives oral polio vaccine at Thandaung township, complain of sudden onset of weakness of arms Kayin State, 21 July 2019 and/or legs. Oral polio vaccine is the vaccine Is there a cure for polio? recommended for polio eradication Can it be prevented? There is no cure for polio. The disease can severely paralyze, or even kill, an infected child. Is the polio vaccine safe? Oral polio vaccine is one of the safest vaccines Polio can be prevented by immunizing a child with ever developed. It is so safe it can be given to sick approrpiate vaccination. There are currently two children and newborns. Since 1961, when oral effective polio vaccines, the inactivated poliovirus polio vaccine was introduced, two billion children vaccine (IPV) and the live attenuated oral polio have been immunized against polio globally. vaccine (OPV). This is estimated to have saved at least 16 million children from permanent paralysis by polio, world- wide. It is also safe to administer multiple doses of polio vaccine to children. -
This Podcast on Meningitis Vaccinations for Adolescents
Meningitis Immunization for Adolescents [Announcer] This podcast is presented by the Centers for Disease Control and Prevention. CDC - safer, healthier people. [Susan Laird] Welcome to this podcast on meningitis immunizations for adolescents. I’m Susan Laird, your host. Here to discuss this topic is Dr. Tom Clark, an epidemiologist with CDC’s National Center for Immunization and Respiratory Diseases. Thanks for coming, Dr. Clark. [Dr. Clark] Well, thank you for having me. [Susan Laird] So, tell us about meningococcal disease. [Dr. Clark] Well, meningococcal disease is an infection caused by a bacteria called Neisseria meningitidis. It can be a life-threatening infection. People may be most familiar with this germ as a cause of meningitis, but there are other forms of the disease as well. Meningitis makes up about half of all cases. Other infections can occur, even though they’re less common. For example, bloodstream infection, with or without meningitis and pneumonia can also occur. In meningitis, the infection causes inflammation of the protective fluid and lining around the brain and the spinal cord which are called the meninges. Symptoms include fever, severe headache, neck stiffness, rash, nausea, vomiting, confusion, and sleepiness. Meningitis is serious, so people who develop these symptoms should seek medical attention immediately. [Susan Laird] Is viral meningitis different from bacterial meningitis? [Dr. Clark] It is. Several bacteria can cause meningitis; meningococcal meningitis is one of the most important and most serious. But, meningitis can also be caused by viruses. About 90 percent of viral meningitis is caused by viruses known as enteroviruses. Viral meningitis is more common during the summer and the fall and can be serious, but is rarely fatal in people with normal immune systems. -
Neurological Manifestations of COVID-19 (SARS-Cov-2): a Review
Journal Articles 2020 Neurological Manifestations of COVID-19 (SARS-CoV-2): A Review MU Ahmed M Hanif MJ Ali MA Haider D Kherani See next page for additional authors Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles Part of the Neurology Commons Recommended Citation Ahmed M, Hanif M, Ali M, Haider M, Kherani D, Memon G, Karim A, Sattar A. Neurological Manifestations of COVID-19 (SARS-CoV-2): A Review. 2020 Jan 01; 11():Article 6474 [ p.]. Available from: https://academicworks.medicine.hofstra.edu/articles/6474. Free full text article. This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works. For more information, please contact [email protected]. Authors MU Ahmed, M Hanif, MJ Ali, MA Haider, D Kherani, GM Memon, AH Karim, and A Sattar This article is available at Donald and Barbara Zucker School of Medicine Academic Works: https://academicworks.medicine.hofstra.edu/articles/6474 MINI REVIEW published: 22 May 2020 doi: 10.3389/fneur.2020.00518 Neurological Manifestations of COVID-19 (SARS-CoV-2): A Review Muhammad Umer Ahmed 1*, Muhammad Hanif 2, Mukarram Jamat Ali 3, Muhammad Adnan Haider 4, Danish Kherani 5, Gul Muhammad Memon 6, Amin H. Karim 5,7 and Abdul Sattar 8 1 Ziauddin University and Hospital, Ziauddin Medical College, Karachi, Pakistan, 2 Khyber Medical College Peshawar, -
2021 Medicare Vaccine Coverage Part B Vs Part D
CDPHP® Medicare Advantage Vaccine Coverage Guide Part B (Medical) vs. Part D (Pharmacy) Medicare Part B (Medical): Medicare Part D (Pharmacy): Vaccinations or inoculations Vaccinations or inoculations are included when the administration is (except influenza, pneumococcal, reasonable and necessary for the prevention of illness. and hepatitis B for members at risk) are excluded unless they are directly related to the treatment of an injury or direct exposure to a disease or condition. • Influenza Vaccine (Flu) • BCG Vaccine • Pneumococcal Vaccine • Diphtheria/Tetanus/Acellular Pertussis Vaccine (ADACEL, (Pneumovax, Prevnar 13) BOOSTRIX, DAPTACEL, INFANRIX) • Hepatitis B Vaccine • Diphtheria/Tetanus/Acellular Pertussis/Inactivated Poliovirus (Recombivax, Engerix-B) Vaccine (KINRIX, QUADRACEL) for members at moderate • Diphtheria/Tetanus Vaccine (DT, Td, TDVAX, TENIVAC) to high risk • Diphtheria/Tetanus/Acellular Pertussis/Inactivated Poliovirus Vac • Other vaccines when directly cine/ Haemophilus Influenzae Type B Conjugate Vaccine (PENTACEL) related to the treatment of an • Diphtheria/Tetanus/Acellular Pertussis/Inactivated Poliovirus injury or direct exposure to a Vaccine/Hepatitis B Vaccine (PEDIARIX) disease or condition, such as: • Haemophilus Influenzae Type B Conjugate Vaccine (ActHIB, PedvaxHIB, • Antivenom Sera Hiberix) • Diphtheria/Tetanus Vaccine • Hepatitis A Vaccine, Inactivated (VAQTA) (DT, Td, TDVAX, TENIVAC) • Hepatitis B Vaccine, Recombinant (ENGERIX-B, RECOMBIVAX HB) • Rabies Virus Vaccine for members at low risk (RabAvert, -
IRES Knocks out Rabies
RESEARCH HIGHLIGHTS VIRAL PATHOGENESIS IRES knocks out rabies Non-segmented negative-strand from poliovirus or human rhinovirus Infection of neurons with RNA RNA viruses that can infect neurons type 2 (HRV2) enables downregula- viruses is initially controlled by in the central nervous system include tion of phosphoprotein expression interferon-β (IFNβ) and subsequently measles virus, mumps virus, Borna at the level of translation and can by virus-specific antibodies and virus, the emerging deadly Nipah render rabies virus avirulent. T-cell derived IFNβ. The rabies virus and Hendra viruses and rabies virus. Although rabies and other phosphoprotein, which is an essential Until now there has been no method non-segmented negative-strand cofactor of the viral polymerase and available to control the expression RNA viruses can replicate in all also has a role in encapsidation of of individual genes of these viruses. cell types, positive-strand RNA replicated genomes, functions to According to a report published in viruses, such as poliovirus and dampen the host response by coun- the Journal of Virology, replacing the HRV2, have a restricted host range. teracting the production of IFN. The transcription signals of the rabies There is evidence that IRESs in the most striking finding from this study virus phosphoprotein gene with 5′-untranslated regions of positive- is that translational attenuation of internal ribosome entry sites (IRESs) strand RNA viruses are subject to phosphoprotein through insertion of cell-type inhibition and can mediate IRESs from poliovirus or HRV2 lim- cell-type specificity. To test whether ited the ability of recombinant rabies Corbis IRESs can affect gene expression of viruses to counteract the production non-segmented negative-strand RNA of IFN, as shown by the failure of viruses, Marschalek et al. -
Viral Meningitis Fact Sheet
Viral ("Aseptic") Meningitis What is meningitis? Meningitis is an illness in which there is inflammation of the tissues that cover the brain and spinal cord. Viral or "aseptic" meningitis, which is the most common type, is caused by an infection with one of several types of viruses. Meningitis can also be caused by infections with several types of bacteria or fungi. In the United States, there are between 25,000 and 50,000 hospitalizations due to viral meningitis each year. What are the symptoms of meningitis? The more common symptoms of meningitis are fever, severe headache, stiff neck, bright lights hurting the eyes, drowsiness or confusion, and nausea and vomiting. In babies, the symptoms are more difficult to identify. They may include fever, fretfulness or irritability, difficulty in awakening the baby, or the baby refuses to eat. The symptoms of meningitis may not be the same for every person. Is viral meningitis a serious disease? Viral ("aseptic") meningitis is serious but rarely fatal in persons with normal immune systems. Usually, the symptoms last from 7 to 10 days and the patient recovers completely. Bacterial meningitis, on the other hand, can be very serious and result in disability or death if not treated promptly. Often, the symptoms of viral meningitis and bacterial meningitis are the same. For this reason, if you think you or your child has meningitis, see your doctor as soon as possible. What causes viral meningitis? Many different viruses can cause meningitis. About 90% of cases of viral meningitis are caused by members of a group of viruses known as enteroviruses, such as coxsackieviruses and echoviruses. -
Vaccine Names and Abbreviations Vaccine Names and Abbreviations Many Vaccines Are Documented in an Abbreviation and Not by Their Full Name
Vaccine Names and Abbreviations Vaccine Names and Abbreviations Many vaccines are documented in an abbreviation and not by their full name. This page is designed to assist you in interpreting both old and new immunization records such as the yellow California Immunization Record, the International Certificate of Vaccination (Military issued shot record) or the Mexican Immunization Card described in the shaded sections. Vaccine Abbreviation/Name What it Means Polio Oral Polio oral poliovirus vaccine (no longer used in U.S.) OPV Orimune Trivalent Polio TOPV Sabin oral poliovirus Inactivated Polio injectable poliovirus vaccine eIPV IPOL IPV Pentacel combination vaccine: DTaP/Hib/IPV Pediarix combination vaccine: diphtheria, tetanus, acellular pertussis, Haemophilus influenzae type b and inactivated poliovirus (DTaP/IPV/Hep B) DTP or DPT combination vaccine: diphtheria, tetanus, pertussis (no longer DTP Tri-Immunol available in U.S.) (Diphtheria, Tetanus, Pertussis) Triple combination vaccine: difteria, tétano, tos ferina (diphtheria, tetanus pertussis) DT combination vaccine: diphtheria and tetanus vaccine (infant vaccine without pertussis component used through age 6) DTaP combination vaccine: diphtheria, tetanus and acellular pertussis DTaP/Tdap Acel-Imune Certiva (Diphtheria, Tetanus, acellular Daptacel Pertussis) Infanrix Tripedia Tdap combination vaccine: tetanus, diphtheria, acellular pertussis Adacel (improved booster vaccine containing pertussis for adolescents Boostrix and adults) DTP-Hib combination vaccine: diphtheria, tetanus,